- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02115295
Kladribin, Idarubicin, Cytarabin och Venetoclax vid behandling av patienter med akut myeloisk leukemi, högriskmyelodysplastiskt syndrom eller kronisk myeloid leukemi i blastisk fas
Fas II-studie av Cladribine Plus Idarubicin Plus Cytarabin (ARAC) hos patienter med AML, HR MDS eller Myeloid Blast Fas av KML
This phase II trial studies how well cladribine, idarubicin, cytarabine, and venetoclax work in patients with acute myeloid leukemia, high-risk myelodysplastic syndrome, or blastic phase chronic myeloid leukemia. Drugs used in chemotherapy, such as cladribine, idarubicin, cytarabine, and venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Studieöversikt
Status
Betingelser
- Akut myeloid leukemi
- Tidigare behandlat myelodysplastiskt syndrom
- Sekundär akut myeloid leukemi
- Obehandlad akut myeloid leukemi hos vuxna
- Myelodysplastiskt syndrom
- Återkommande akut myeloid leukemi
- Refraktär Akut Myeloid Leukemi
- Blast Phase Kronisk myelogen leukemi, BCR-ABL1 positiv
- Återkommande kronisk myelogen leukemi, BCR-ABL1 positiv
- Refraktär kronisk myelogen leukemi, BCR-ABL1 positiv
- de Novo myelodysplastiskt syndrom
- Akut bifenotypisk leukemi
- Spränger 10 procent eller mer av benmärgskärnade celler
- Spränger 10 procent eller mer av vita blodkroppar i perifert blod
Detaljerad beskrivning
Primary Objectives:
I. To determine the complete response rate (CR) of cladribine in combination with idarubicin and cytarabine (araC) in patients with acute myeloid leukemia (AML), high risk (HR) myelodysplastic syndrome (MDS), or myeloid blast phase of chronic myeloid leukemia (CML).
Secondary Objectives:
I. To determine the overall response rate (ORR) of cladribine in combination with idarubicin and araC in patients with AML, HR MDS, or myeloid blast phase of CML.
II. To assess overall survival (OS) and event free survival (EFS) of patients treated with cladribine, idarubicin, and araC (cytarabine).
III. To assess the duration of response to the combination in patients with AML, HR MDS, or myeloid blast phase of CML.
IV. To determine the safety and tolerability of the combination in patients with AML, HR MDS, or myeloid blast phase of CML.
Exploratory Objectives:
I. To study and describe the relationship between pretreatment patient/disease characteristics (including AML-associated molecular abnormalities) and outcome.
II. To identify molecular biomarkers predictive of response to therapy.
III. To study and describe the relationship between patient/disease characteristics, use of intrathecal prophylaxis, and incidence of leptomeningeal disease.
IV. To study the trajectories of leukemia mutations and molecular minimal residual disease (MRD) during the therapy.
OUTLINE:
INDUCTION: Patients receive cladribine intravenously (IV) and cytarabine IV over 1-2 hours on days 1-5 and idarubicin IV over 30-60 minutes on days 1-3. Patients with untreated AML and MDS also receive venetoclax orally (PO) on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO twice daily (BID) on days 6-19 or gilteritinib PO once daily (QD) on days 1-14. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity.
CONSOLIDATION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-3 and idarubicin IV over 30-60 minutes on days 1-2. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 6-12 months.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
Kontakter och platser
Studiekontakt
- Namn: Tapan Kadia
- Telefonnummer: 713-792-7305
- E-post: tkadia@mdanderson.org
Studieorter
-
-
Texas
-
Houston, Texas, Förenta staterna, 77030
- Rekrytering
- M D Anderson Cancer Center
-
Kontakt:
- Tapan M. Kadia
- Telefonnummer: 713-792-7305
-
Huvudutredare:
- Tapan M. Kadia
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Patients with a diagnosis of AML, Acute Biphenotypic Leukemia, or high risk MDS (>/= 10% blasts or IPSS >/= intermediate-2) will be eligible. Patients with CML in Myeloid Blast Phase are also eligible.
-
For Frontline cohort (1 or 4): No prior potentially-curative therapy for leukemia. Prior therapy with hydroxyurea, hematopoietic growth factors, azacytidine, decitabine, ATRA, or a total dose of cytarabine up to 2g (for emergency use for stabilization) is allowed. Patients deemed able to receive venetoclax (ie. insurance clearance) will be assigned to Frontline cohort 4. Patients with secondary AMLwho have been treated for their antecedent myeloid neoplasm will be enrolled into the separate Secondary AML cohort.
-
For Salvage cohort: Patients with previously treated, relapsed or refractory AML, Acute Biphenotypic Leukemia, or CML in Myeloid Blast Phase are eligible.
-
Age </= 65 years.
-
Adequate organ function as defined below:
- liver function (bilirubin < 2mg/dL, AST and/or ALT <3 x ULN - or <5 x ULN if related to leukemic involvement)
- kidney function (creatinine < 1.5 x ULN ).
- known cardiac ejection fraction of > or = 45% within the past 6 months
-
ECOG performance status of ≤ 2.
-
A negative urine pregnancy test is required within 1 week for all women of childbearing potential prior to enrolling on this trial.
-
Patient must have the ability to understand the requirements of the study and signed informed consent. A signed informed consent by the patient is required prior to their enrollment on the protocol.
Exclusion Criteria:
- Pregnant women are excluded from this study because the agents used in this study have the potential for teratogenic or abortifacient effects. Because there is a potential risk for adverse events in nursing infants secondary to treatment of the mother with the chemotherapy agents, breastfeeding should also be avoided.
- Uncontrolled intercurrent illness including, but not limited to active uncontrolled infection, symptomatic congestive heart failure (NYHA Class III or IV), unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patient with documented hypersensitivity to any of the components of the chemotherapy program.
- Men and women of childbearing potential who do not practice contraception. Women of childbearing potential and men must agree to use contraception prior to study entry and for the duration of study participation.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Treatment (cladribine, cytarabine, idarubicin)
INDUCTION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-5 and idarubicin IV over 30-60 minutes on days 1-3. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD on days 1-14. Treatment repeats every 28 days for up to 2 cycles in the absence of disease progression or unacceptable toxicity. CONSOLIDATION: Patients receive cladribine IV and cytarabine IV over 1-2 hours on days 1-3 and idarubicin IV over 30-60 minutes on days 1-2. Patients with untreated AML and MDS also receive venetoclax PO on days 2-8. AML patients with known FLT3-ITD or FLT3 kinase domain mutations may receive midostaurin PO BID on days 6-19 or gilteritinib PO QD. Treatment repeats every 28 days for up to 5 cycles in the absence of disease progression or unacceptable toxicity. |
Correlative studies Given IV
Andra namn:
Given IV
Andra namn:
Given IV
Andra namn:
Given PO
Andra namn:
Given PO
Andra namn:
Given PO
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Complete response (CR) rate
Tidsram: Up to 12 months
|
CR rate will be determined. |
Up to 12 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Overall response rate (ORR)
Tidsram: Up to 12 months
|
ORR will be determined. |
Up to 12 months
|
|
Overall survival (OS)
Tidsram: Up to 12 months
|
OS will be assessed. |
Up to 12 months
|
|
Event-free survival (EFS)
Tidsram: Up to 12 months
|
EFS will be assessed. |
Up to 12 months
|
|
Duration of response
Tidsram: Up to 12 months
|
Duration of response will be assessed. |
Up to 12 months
|
|
Incidence of toxicities
Tidsram: Up to 12 months
|
Safety and tolerability of cladribine in combination with idarubicin and cytarabine will be determined. |
Up to 12 months
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Use of intrathecal prophylaxis
Tidsram: Up to 12 months
|
The relationship between patient/disease characteristics and use of intrathecal prophylaxis will be studied and described. |
Up to 12 months
|
|
Incidence of leptomeningeal disease
Tidsram: Up to 12 months
|
The relationship between patient/disease characteristics and incidence of leptomeningeal disease will be studied and described. |
Up to 12 months
|
Samarbetspartners och utredare
Sponsor
Samarbetspartners
Utredare
- Huvudutredare: Tapan M Kadia, M.D. Anderson Cancer Center
Publikationer och användbara länkar
Allmänna publikationer
- Kadia TM, Reville PK, Borthakur G, Yilmaz M, Kornblau S, Alvarado Y, Dinardo CD, Daver N, Jain N, Pemmaraju N, Short N, Wang SA, Tidwell RSS, Islam R, Konopleva M, Garcia-Manero G, Ravandi F, Kantarjian HM. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2021 Aug;8(8):e552-e561. doi: 10.1016/S2352-3026(21)00192-7.
- Morita K, Kantarjian HM, Wang F, Yan Y, Bueso-Ramos C, Sasaki K, Issa GC, Wang S, Jorgensen J, Song X, Zhang J, Tippen S, Thornton R, Coyle M, Little L, Gumbs C, Pemmaraju N, Daver N, DiNardo CD, Konopleva M, Andreeff M, Ravandi F, Cortes JE, Kadia T, Jabbour E, Garcia-Manero G, Patel KP, Futreal PA, Takahashi K. Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol. 2018 Jun 20;36(18):1788-1797. doi: 10.1200/JCO.2017.77.6757. Epub 2018 Apr 27.
- Goulart H, Jabbour E, Short NJ, Kadia TM, Pemmaraju N, Takahashi K, Ravandi F, Konopleva M, Jain N. A Phase I/II Trial of Ruxolitinib with Chemotherapy for Patients with Relapsed and/or Refractory Philadelphia-like Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2025 Nov;25(11):800-807. doi: 10.1016/j.clml.2025.05.013. Epub 2025 May 20.
- Goulart H, Kantarjian H, Borthakur G, Daver N, DiNardo CD, Jabbour E, Pemmaraju N, Alvarado Y, Atluri H, Yilmaz M, Haddad FG, Marx KR, Rausch C, Loghavi S, Jain N, Garcia-Manero G, Ravandi-Kashani F, Kadia TM. Cladribine, idarubicin, and cytarabine (CLIA) for patients with relapsed and/or refractory acute myeloid leukemia: A single-center, single-arm, phase 2 trial. Cancer. 2025 Apr 15;131(8):e35840. doi: 10.1002/cncr.35840.
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Beräknad)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Patologiska processer
- Neoplasmer
- Kronisk sjukdom
- Sjukdomsegenskaper
- Immunsystemets sjukdomar
- Neoplasmer efter histologisk typ
- Hematologiska sjukdomar
- Neoplastiska processer
- Lymfatiska sjukdomar
- Lymfoproliferativa störningar
- Immunproliferativa störningar
- Leukemi, myeloid
- Benmärgssjukdomar
- Leukemi, lymfoid
- Leukemi
- Myeloproliferativa störningar
- Celltransformation, neoplastisk
- Carcinogenes
- Patologiska tillstånd, tecken och symtom
- Hemiska och lymfsjukdomar
- Leukemi, Myeloid, Akut
- Myelodysplastiska syndrom
- Leukemi, Myelogen, Kronisk, BCR-ABL positiv
- Blast Crisis
- Leukemi, Bifenotypisk, Akut
- Organiska kemikalier
- Heterocykliska föreningar, 1-ring
- Heterocykliska föreningar
- Heterocykliska föreningar, 2-ring
- Heterocykliska föreningar, smältring
- Nukleinsyror, nukleotider och nukleosider
- Kolväten
- Kolväten, cykliska
- Kolhydrater
- Polycykliska aromatiska kolväten
- Kolväten, aromatisk
- Polycykliska föreningar
- Glykosider
- Puriner
- Cytidin
- Pyrimidin nukleosider
- Pyrimidiner
- Nukleosider
- Ribonukleosider
- Arabinonukleosider
- Anthracykliner
- Naftakener
- Aminoglykosider
- Daunorubicin
- Deoxyribonukleosider
- 2-kloroadenosin
- Adenosin
- Purin nukleosider
- Deoxyadenosiner
- Cytarabin
- Kladribin
- Idarubicin
- venetoklax
- gilteritinib
- midostaurin
Andra studie-ID-nummer
- 2012-0648
- 2012-0648 (Annan identifierare: M D Anderson Cancer Center)
- NCI-2014-01103 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .